NASDAQ:ALNY
Alnylam Pharmaceuticals Stock News
$150.47
-0.90 (-0.595%)
At Close: May 10, 2024
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a web
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from th
Why virus stocks are driving market volatility
04:00pm, Saturday, 30'th May 2020
The market’s erratic response to lukewarm medical research for COVID-19 treatment and vaccine candidates isn’t expected to slow down as investors pin their...
Alnylam's NDA Accepted, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ALNY)
04:50am, Friday, 29'th May 2020
Alnylam's Lumasiran NDA has been accepted. Argenx reports positive data from Efgartigimod trial. Co-Diagnostics discusses its coronavirus test kit.
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen
12:00am, Friday, 29'th May 2020
Johnson & Johnson today announced that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products
UBS Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $122
01:05pm, Thursday, 28'th May 2020Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA
01:47pm, Wednesday, 27'th May 2020
Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.
Alnylam Pharmaceuticals : to Webcast Presentations at Upcoming June Investor Conferences | MarketScreener
08:02pm, Tuesday, 26'th May 2020Alnylam to Webcast Presentations at Upcoming June Investor Conferences
08:00pm, Tuesday, 26'th May 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
New Coronavirus Vaccine Candidate: Novavax Starting Clinical Trials Of NVX-COV2373 To Fight Pandemic
02:36pm, Tuesday, 26'th May 2020
The first phase of the trial will enroll 130 healthy individuals ages 18 to 59 and take place in Australia while phase 2 will be conducted in multiple countries and widen the age range.
Pfizer Is Charging Ahead With A Coronavirus Vaccine — Is PFE Stock A Buy?
12:00pm, Tuesday, 26'th May 2020
Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?
New Coronavirus Vaccine To Send Virus' Spike Protein To Activate Body's Immune Response
12:00pm, Tuesday, 26'th May 2020
Novavax is now beginning its clinical trials.
Alnylam Announces FDA Has Granted Priority Review Of Lumasiran New Drug Application For Primary Hyperoxaluria Type 1
11:01am, Tuesday, 26'th May 2020Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT
11:00am, Tuesday, 26'th May 2020
Q1 2020 Alnylam Pharmaceuticals Inc Earnings Call
